Evkeeza Generic Name & Formulations
Mechanism of Action
Limitations of Use
Evkeeza Dosage and Administration
Adults and Children
<5yrs: not established. Give by IV infusion over 60mins. ≥5yrs: 15mg/kg once monthly (every 4 weeks).
Evkeeza Boxed Warnings
Discontinue if serious hypersensitivity reactions occur; monitor and treat appropriately. Assess LDL-C when clinically appropriate; effects may be measured as early as 2 weeks after initiation. Embryo-fetal toxicity. Advise females of reproductive potential to use effective contraception during and for ≥5 months after the last dose. Pregnancy: exclude status prior to initiation. Nursing mothers.
Mean (standard deviation) steady-state trough concentration: 266 (120) mg/L in adults. Mean (standard deviation) Cmax at the end of infusion: 718 (183) mg/L in adults.
Steady-state volume of distribution: ~4.7 L in adults.
Evinacumab-dgnb elimination is mediated via parallel linear and non-linear pathways. The elimination half-life is a function of serum evinacumab-dgnb concentrations, and is not a constant. Evinacumab-dgnb is not likely to undergo renal excretion.
Evkeeza Adverse Reactions
Nasopharyngitis, influenza-like illness, dizziness, rhinorrhea, nausea, fatigue; hypersensitivity reactions.
Evkeeza Clinical Trials
Evkeeza Patient Counseling